Acid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine-1-phosphate. AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target. Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the non-metastatic clone PC-3/S. Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases.
INTRODUCTION
Cancer cells develop a lipogenic phenotype that supports the energy and membrane synthesis requirements associated with the enhanced proliferation and survival under stress inherent to malignant progression (1) (2) . The recognition of the importance of this phenotype in cancer has led to the use of enzymes of lipid metabolism as markers to monitor neoplastic progression and response to therapy, as well as to the development of drugs targeted at key lipogenic enzymes, such as fatty acid synthase (FASN) (2) (3) . The excess fatty acid synthesis that results from the coordinated activation of lipogenic enzymes in many types of cancer leads to the accumulation of palmitate, that needs to be further processed by the cells due to the toxic effects of its accumulation. One pathway that many neoplastic cells activate in order to offset the toxic accumulation of palmitate is its PPAR-dependent funneling to eventually form triglycerides, which can be further used as energy stores (4) . A second pathway followed by palmitate is the condensation of palmitoyl CoA with Lserine, leading to the synthesis of ceramides (5) . The accumulation of ceramides also poses a problem for cell survival because of its pro-apoptotic consequences (6) (7) (8) . This can be counteracted by activities that convert ceramides to a variety of metabolites, including sphingosines through deacylation catalyzed by ceramidases.
Sphingosines can be converted into the growth-and survival-promoting sphingosine-1-phosphate (S1P) through the action of sphingosine kinases (8) . S1P can be either irreversibly degraded by S1P lyase or, alternately, S1P may be re-utilized by sequential dephosphorylation and acylation for ceramide synthesis. The importance of ceramidases in the context of cancer is supported by the observation that their by guest, on October 22, 2017 www.jlr.org Downloaded from inhibition by drugs or RNAi severely compromises the growth and survival under stress of tumor cells (9) .
De novo ceramide biosynthesis requires the coordinate action of serine palmitoyl transferase and ceramide synthase to generate ceramide. This process begins with the condensation of serine and palmitoyl-CoA to form 3-ketosphinganine (5) , which is reduced to the sphingoid base sphinganine and acylated by ceramide synthase to generate dihydroceramide. This compound is oxidized to ceramide by introduction of a trans-4,5 double bond. This pathway can be stimulated by drugs and ionizing radiation and usually results in a prolonged ceramide elevation (10) .
Once generated, ceramide may amass or may be converted into a variety of metabolites. Phosphorylation by ceramide kinase (11) generates ceramide 1-phosphate, while deacylation by either alkaline, neutral or acid ceramidase -the products of different genes (12) -yields sphingosine, which may be phosphorylated by sphingosine kinase to S1P. Two distinct sphingosine kinases have been cloned.
These two isoforms differ in temporal patterns of expression during development, are expressed in different tissues, and possess distinct kinetic properties (13) , implying that they perform different cellular functions. Ceramide may also be converted back to sphingomyelin (SM) by transfer of phosphorylcholine from phosphatidylcholine via SM synthases (14) . Alternatively, it can be glycosylated by glucosylceramide synthase to form glucosylceramide, which may be further modified by various enzymes in the Golgi apparatus to form complex glycosphingolipids (15) .
Many tumor types express high levels of acid ceramidase (AC). Specifically, the expression levels of AC in prostate cancer have been reported to be elevated relative to normal prostate tissue (16) (17) . Prostate cancer (PC) is the most prevalent neoplasia in men in industrialized nations (18) . Although PC is frequently initially by guest, on October 22, 2017 www.jlr.org Downloaded from sensitive to hormonal deprivation therapies and follow indolent clinical courses, a significant proportion of cases eventually become resistant to such therapeutic approaches, accompanied with aggressive growth, establishment of metastasis and tumors that are highly resistant to conventional chemotherapeutic regimes (19) (20) .
Two major challenges in PC are to find predictive markers that identify those tumors most likely to follow a hormone-independent, aggressive clinical course, as aids to decide early intervention, and also to identify molecular targets for improved therapies of castration-resistant cases that respond poorly to conventional chemotherapeutic regimes. Here, we provide new evidence to reinforce the notion that the acid ceramidase ASAH1 is a valid therapeutic target in advanced prostate cancer, and characterize new potent and specific inhibitors of AC.
METHODS

Cells and reagents
PC-3/Mc and PC-3/S cells (21) were grown in RPMI1640 medium supplemented with 10% fetal bovine serum, non-essential amino acids, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin and 100 µg/mL streptomycin (all from PAA, Ontario, Canada). Fibroblasts from a Farber patient (FD, wild type) and FD transformed to stably overexpress AC (FD10X) were grown in a humidified 5% CO 2 atmosphere at 37 ºC in DMEM medium supplemented as above.
Transient transfection of fibroblasts
Twenty-four hours before transfection, cells were plated at a density of 2. were seeded in 96-well plates (Nunc, Roskilde, Denmark). The following day, medium was replaced by 100 μL fresh medium containing 40 µM RBM14 fluorogenic substrate, incubated for 3 h at 37 °C in a 5% CO 2 atmosphere, and the assay continued as above.
Papain activity
Papain activity was determined in 96-well plates by a modification of the reported procedure (23) . 
Sphingolipid analysis by UPLC/MS
The liquid chromatography-mass spectrometry equipment consisted of a Waters Aquity UPLC system connected to a Waters LCT Premier orthogonal accelerated time of flight mass spectrometer (Waters, Millford, MA), operated in positive electrospray ionization mode. Full scan spectra from 50 to 1500 Da were acquired and individual spectra were summed to produce data points every 0.2 s. Mass accuracy and reproducibility were maintained by using an independent reference spray by the LockSpray interference. The analytical column was a 100 mm × 2. The amplification levels of RN18S1 and HMBS were used as internal references to estimate the relative levels of specific transcripts, and relative quantification was determined by the ∆∆Cp method. All determinations were done in triplicate.
Cell cycle analysis
Cells were seeded in 6-well Corning plates (Corning, NY), detached with Trypsin/EDTA/1% BSA, washed twice, resuspended in PBS, and fixed at 4 °C for at least 2 h by dropwise addition of 70% ethanol. Subsequently, cells were washed with PBS/50 mM EDTA/1% BSA and incubated with 1 mg/mL RNase A (Sigma) at 37 °C for 1 hour and 0.1 mg/mL propidium iodide (Sigma, Alcobendas, Madrid, Spain).
DNA content was determined in a Cytomics FC500 instrument (Coulter, Hialeah, FL), and cell cycle distribution analyzed with Multicycle. All determinations were done in triplicate.
Anchorage-independent growth
For soft-agar colony formation assays, 0.5% agar in complete culture medium was (1 mL). The resulting solution was stirred for 1 h at room temperature and concentrated at reduced pressure. The residue was taken up in CH 2 Cl 2 (2 mL),
washed with saturated aqueous NaHCO 3 solution (3 x 0.5 mL) and the solvent was evaporated to give a crude mixture that was purified by flash chromatography on silica gel using a gradient of 0-5% CH 2 Cl 2 /MeOH to afford the pure amide in 70-85% yield. camera.
SABRAC: N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl
RBM1-12: N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]-
RBM1-13: N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]-2-methylacrylamide
RBM1-19: N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]acrylamide
Statistical analysis
Significance was determined by the two-tailed unpaired t-test using the Graph Pad No significant differences between free bases and long chain phosphates were detected between the two cell lines (not shown).
Enzyme activity determination showed that the highly aggressive and metastatic PC-3/Mc cells displayed levels of AC activity that were 2.5 to 4 times higher than those of PC-3/S cells, determined either in cell lysates at acidic pH or in intact cells (Fig. 1G ) using a fluorogenic assay (22) . Several evidences support that the bulk of the ceramidase activity detected in these cells is due to AC. distinct sequences on the ASAH1 mRNA. Three of these shRNAs were effective at specifically decreasing ASAH1 mRNA levels with variable efficacies, ranging from 90 to 60% (Fig 2A) . This gene knockdown was paralleled by a corresponding inhibition of the AC activity in these cells (Fig 2A) . The silencing efficacies of shRNAs 399 and 402 were confirmed by Western blotting (Fig 2B) .
The (Fig. 3A) . However, when seeded at a density of 500 cells/cm 2 , ASAH1-knockdown cells showed a significantly reduced growth rate compared to control cells (Fig. 3B ). This suggests that ASAH1 control cells at all initial seeding densities, with more pronounced effects at the lowest initial seeding density studied (Fig. 3C-D) .
In agreement with the weak effect of ASAH1 knockdown on the growth of PC-3/Mc cells in standard culture conditions, only one of the two ASAH1-specific shRNAs caused a modest decline of the G1 population with an increased G2-M population (Fig. 3E) . (Fig. 5B) . While RBM1-12, RBM1-13, and SABRAC maintained their inhibitory activities in the in vitro assay, RBM1-18 had no inhibitory activity in cell lysates (Fig. 5B) . Therefore, compounds RBM1-12, RBM1-13, and SABRAC were selected for further studies. To assess their specificity, the three compounds were tested for their effects on neutral ceramidase (NC) using the standard substrate (28) and FD cells transiently transfected with the ASAH2 gene. None of the compounds inhibited NC (Fig. 5C ), attesting to their specificity as inhibitors of acid ceramidase. In vitro dose-response determinations showed that SABRAC was the best inhibitor, with an IC 50 value of 52 nM, followed by RBM1-12 (IC 50 = 0.53 µM) and RBM1-13, which exhibited the lower potency (IC 50 = 11.2 µM) (Fig. 5D) exponential decay versus incubation time at the two protein concentrations tested (Suppl. Fig. 1 ), indicating an irreversible type of inhibition.
Neither SABRAC nor RBM1-12 inhibited the activity of the cysteine protease papain, while chymostatin completely blocked papain activity at the standard concentrations (Suppl . Fig 2A) . On the other hand, at conditions under which SABRAC inhibited AC, AC activity was unaffected by the cysteine protease inhibitor E64d (Suppl. Fig. 2B ).
Effects of AC inhibitors on the growth of PC-3/Mc cells
We next tested the effects of RBM1-12, RBM1-13 and SABRAC on the growth properties of PC-3/Mc cells. First, the inhibitory potency of these compounds on AC was tested by incubating the cells with increasing doses for 48 hours, and AC activity determined in cell lysates using a fluorogenic assay. Under these conditions, the inhibition of AC by RBM1-12 and SABRAC was dose-dependent (RBM1-12: 1 µM < IC50 < 5 µM; SABRAC: IC50 < 1 µM) (Fig. 6A) . Surprisingly, RBM1-13, which had shown to be a good AC inhibitor in FD10X intact cells and cell lysates ( The abundance of complex sphingolipids such as SM or CMH was not significantly affected by any of the compounds, except for the levels of CMH in cells treated with RBM1-12 at 5 µM, which increased 50% over controls (Fig. 6B) . This is in contrast with the effect of stably knocking down ASAH1 in PC-3/Mc cells, which caused the accumulation of these complex sphingolipids ( Fig. 2D-E exerting cytotoxic activity on these cells, had less potent inhibitory activity on the growth of these cells on plastic, and showed no effect on their capacity to grow in anchorage-independent conditions.
Expression of ASAH1 in non-metastatic and metastatic prostate cancer
It has previously been reported that ASAH1 is expressed in a number of tumor types, including PC, at levels higher than in normal tissues (17) . However, thus far its expression in PC has not been reported by immunohistochemistry, which permits to correlate staining intensities (as surrogates of expression levels) with morphological parameters. We used a ASAH1-specific antibody ( Fig. 1H and 2B ) to analyze by immunohistochemistry a total of 33 samples from prostate cancer patients, containing tumoral glands, glands with normal morphologies and glands with characteristics of the preneoplastic lesion prostate intraepithelial neoplasia (PIN). All epithelial structures stained for ASAH1, albeit at varying intensities ( Fig.   7A-C) . In a range of staining intensities from 1 to 3, most normal or neoplastic structures were given an intensity score of 2 (72.7% of normal glands, 75% of PIN and 63.6% of tumoral glands; Fig. 7D and Suppl. Fig. 7D and Suppl. Table 2 ). In those cases in which normal and tumoral glands could be evaluated simultaneously in the same sample (22 cases), the ASAH1 staining intensities of normal vs. tumoral glands were scored as equal in 10 cases (45.5%), the staining intensity was scored as stronger in tumoral glands vs.
normal glands in 8 cases (36.4%), while in 4 cases (18.2%) the maximum intensity in tumoral glands was scored as lower than the maximum intensity in normal glands ( Fig. 7E and Suppl. Table 2 ). In several cases, the staining intensity for ASAH1 in tumoral areas was clearly stronger than the staining in adjacent normal glands (Fig.   7C, E) .
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Thus, strong ASAH1 immunostaining in human prostate tissues tended to be associated with prostate adenocarcinoma (Fig. 7D) , an observation that complements previous reports in which immunohistochemical analysis was not performed and thus the specific cell type, either epithelial or stromal, expressing ASAH1 was not determined (17) . On the other hand, with the cases studied here, stronger ASAH1 staining did not show correlations with histological grade (Gleason score), stage or the presence of lymph node metastasis. However, the observation that strong expression of ASAH1 was associated with the preneoplastic PIN lesions more than with normal glands, and, in turn, with prostate adenocarcinoma more than with PIN lesions, suggests that ASAH1 expression levels tend to increase during PC progression.
DISCUSSION
Advanced, hormone-independent, castration-resistant prostate cancer represents a devastating form of the disease that frequently develops from initially less aggressive tumors and that shows resistance to conventional chemotherapeutic agents (18) (19) (20) . In this evolutive process, the progressive dominance in the tumor of cancer stem cells, endowed with high survival and low drug sensitivity (25, 29) , is emerging as crucial. 
